A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA by Christopher W. Murray & David R. Newell & Patrick Angibaud

A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA by Christopher W. Murray & David R. Newell & Patrick Angibaud

Author:Christopher W. Murray & David R. Newell & Patrick Angibaud
Format: pdf
Publisher: Royal Society of Chemistry
Published: 0101-01-01T00:00:00+00:00


Download



Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.